A Study of Bone Turnover Markers in Post-Menopausal Women With Osteoporosis Treated With Monthly Boniva (Ibandronate)
Status:
Completed
Trial end date:
2007-06-01
Target enrollment:
Participant gender:
Summary
This study will determine the rapidity of suppression of the bone resorption marker sCTX in
post-menopausal women with osteoporosis.Other bone turnover markers will also be evaluated.
Patients will be randomised to either monthly Boniva 150mg or placebo, in combination with
vitamin D and calcium supplementation. The anticipated time on study treatment is
approximately 7 months, and the target sample size is <100 individuals.
Phase:
Phase 4
Details
Lead Sponsor:
Hoffmann-La Roche
Treatments:
Calcium Calcium, Dietary Diphosphonates Ergocalciferols Ibandronic Acid Vitamin D Vitamins